Investigational drug · Phase 2
Nemvaleukin
Also called: ALKS 4230
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Solid Tumor.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 7, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "Nemvaleukin"
First trial start
2020
Sep 30, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Nemvaleukin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumor
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Nemvaleukin" as an intervention, largest first.
- Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)Pivotal-lookingTerminated
Mural Oncology, IncIndustry
NCT05092360 · 456 participants · Start Jan 10, 2022 · Primary completion Jan 8, 2025
Drug: Nemvaleukin and Pembrolizumab Combination; Pembrolizumab and 5 more · For: Platinum-resistant Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Tucson, Arizona · 117 sites in all
Mural Oncology, IncIndustry
NCT02799095 · 243 participants · Start Sep 14, 2016 · Primary completion Mar 27, 2023
Drug: ALKS 4230; ALKS 4230 + pembrolizumab · For: Advanced Solid Tumors
Sites: Denver, Colorado; Port Saint Lucie, Florida; Tampa, Florida · 31 sites in all
Mural Oncology, IncIndustry
NCT04830124 · 173 participants · Start Sep 27, 2021 · Primary completion May 8, 2025
Drug: Nemvaleukin Alfa Subcutaneous; Nemvaleukin Alfa Intravenous and 2 more · For: Cutaneous Melanoma; Mucosal Melanoma
Sites: La Jolla, California; Los Angeles, California; Jacksonville, Florida · 41 sites in all
Mural Oncology, IncIndustry
NCT03861793 · 116 participants · Start Feb 26, 2019 · Primary completion Mar 1, 2023
Drug: ALKS 4230; Pembrolizumab · For: Advanced Solid Tumors
Sites: Los Angeles, California; Washington D.C., District of Columbia; Atlanta, Georgia · 48 sites in all
- Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)Active, not recruiting
Mural Oncology, IncIndustry
NCT04592653 · 78 participants (planned) · Start Sep 30, 2020 · Primary completion Jul 2024
Drug: Nemvaleukin alfa; Pembrolizumab · For: Advanced Solid Tumor
Sites: Grand Rapids, Michigan; Houston, Texas; West Valley City, Utah · 6 sites in all
Mural Oncology, IncIndustry
NCT04144517 · 14 participants · Start Feb 5, 2020 · Primary completion Oct 8, 2021
Drug: Nemvaleukin Alfa; Pembrolizumab · For: Squamous Cell Carcinoma of Head and Neck
Sites: Miami, Florida; Atlanta, Georgia; Minneapolis, Minnesota · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Less frequent intravenous dosing of nemvaleukin alfa in patients with advanced solid tumors: the phase 1/2 ARTISTRY-3 trial.
Piha-Paul SA, Call JA, Spira AI, et al. · Oncologist 2025
- Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial.
Calvo E, Boni V, Dumas O, et al. · J Immunother Cancer 2025
- Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1).
Vaishampayan UN, Muzaffar J, Winer I, et al. · J Immunother Cancer 2024
- Correction: Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy.
He K, Puebla-Osorio N, Barsoumian HB, et al. · J Exp Clin Cancer Res 2024
- Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy.
He K, Puebla-Osorio N, Barsoumian HB, et al. · J Exp Clin Cancer Res 2024
- Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeutics.
Phoon YP, Lopes JE, Pfannenstiel LW, et al. · J Immunother Cancer 2024
Also in development for Advanced Solid Tumor
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.